Dr. Karen H. Antman, the deputy director for translational and clinical sciences, has accepted a job as provost of the Boston University Medical Campus and dean of the School of Medicine. And CCR Director Dr. J. Carl Barrett has taken a position with the Novartis Institutes for Biomedical Research as Global Head of Oncology Biomarkers.

"Losing these two individuals with respect to their leadership is, for us, going to be a great loss," Dr. von Eschenbach said. "But, like all great institutions, we have great people who step up." CCR Principal Deputy Director Dr. Robert Wiltrout, he announced, will become the new director of CCR.  Read more  

As part of its transparent, inclusive approach to increasing cancer clinical trials efficiency, decreasing redundancy and administrative burdens, and better coordinating activities to enhance the development and delivery of the best therapies to people with cancer, CTWG welcomes public comment on the draft recommendations. Final  Read more  

The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI). NCI, which was established in 1937, leads the national effort to eliminate the suffering and death due to cancer. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases. For more information on cancer, call 1-800-4-CANCER or visit http://www.cancer.gov. NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.